Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY-162 in Children with ADHD
NCT01536210Phase 3Completed
- Sponsor
- Yuyu Pharma
- Start
- Dec 2011
- Primary completion
- Aug 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YY-162 in attention deficit hyperactivity disorder (ADHD), sponsored by Yuyu Pharma. Started Dec 2011; status: completed.
02
Drugs
YY-162
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01536210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01536210.